What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective

What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective

Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achiev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of travel medicine 2021-06, Vol.28 (4)
Hauptverfasser: Hu, Yinglian, Chen, Simiao
Format: Artikel
Sprache:eng
Schlagworte:
Biomedical Research
China
Clinical trials
Collaboration
Coronaviruses
COVID-19 - prevention & control
COVID-19 Vaccines
Developed countries
Disease transmission
Drug dosages
Epidemics
FDA approval
Government agencies
Humans
Industrialized nations
Infectious diseases
Medicine
Pharmaceutical industry
Politics
Public health
Public Policy
R&D
Research & development
Task forces
Travel medicine
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achieve broad consensus; (ii) strengthen coordination across government agencies and (iii) adopt the state-driven collaborative model.
ISSN:1195-1982
1708-8305
1708-8305
DOI:10.1093/jtm/taab026